Omontys OverviewPeginesatide (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of pegi...
Read more Omontys Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Peginesatide
Recent Omontys Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 1mg/0.5ml, 2mg/0.5ml, 3mg/0.5ml, 4mg/0.5ml, 5mg/0.5ml, 6mg/0.5ml
- Solution: 10mg/ml (10mg/ml), 1mg/0.5ml (1mg/0.5ml), 20mg/2ml (10mg/ml), 2mg/0.5ml (2mg/0.5ml), 3mg/0.5ml (3mg/0.5ml), 4mg/0.5ml (4mg/0.5ml), 5mg/0.5ml (5mg/0.5ml), 6mg/0.5ml (6mg/0.5ml)